

## Phaleria Leaf Extract For Anticancer Composition

### TECHNOLOGY DESCRIPTION

This technology relates to herbal extract of the Phaleria macrocarpa leaves that can be used to treat colon cancer and breast cancer.

### TECHNOLOGY FEATURES

The invention concerns the extract from the Phaleria macrocarpa leaves. The dichloromethane extract from Phaleria macrocarpa leaves is able to inhibit the growth of HT29 and MCF-7 cell lines indicated by decreasing of the cell number as the extract concentration decreases. The invention also can be used as an ingredient in prevention from the breast cancer and the colon cancer. It is suitable to be used as health care supplement, food and beverage product.

### ADVANTAGES

- Able to kill cancer cells
- As prevention of cancer
- Health care supplement

### INDUSTRY OVERVIEW

#### Prospect Industry: Pharmaceutical, Health supplements

The present innovation can be used as an ingredient in prevention from breast and colon cancer. Its application can be found in pharmaceutical field – pill, tablet, powder, capsule, syrup, ointment, cream, supplement, vitamin, food and beverage product. There are currently 250 manufacturers in Malaysia licensed by the Drug Control Authority. Of these, 74 are licensed to produce pharmaceuticals. There are also another 176 manufacturers licensed to produce traditional medicines and 207 for cosmetics. Malaysia's export of pharmaceutical in 2015 valued at RM1.31 billion, increased by 15.8 per cent from a year ago. Medicament and glycosides accounted for 79.8 per cent of Malaysia's total exports of pharmaceutical products in 2015. Higher exports were recorded for glycoside which increased by 47.9 per cent mainly due to increase in exports to USA, Germany, Ireland, PRC and France. Other pharmaceutical products registered increases in 2015 were pharmaceutical goods (non-medicaments) grew by 99.5 per cent, vitamins (48.1 per cent) and hormones (34.6 per cent). Singapore, the USA, Brunei, Hong Kong, Indonesia and Vietnam were Malaysia's major export destinations. Collectively, these six countries accounted for more than 50 per cent of total exports for pharmaceutical in 2015. Destinations that have shown significant growth during the period were: The USA (RM159.1 million, grew by 40.5 per cent); Brunei (RM105 million, 28 per cent); Germany (RM27 million, 252 per cent); Indonesia (RM75.6 million, 26 per cent); and PRC (RM52 million, 42.2 per cent). The pharmaceutical market in Malaysia is set to grow from \$2.3 billion in 2015 to \$3.6 billion by 2020, registering a compound annual growth rate of 9.5%.



**Prof. Dr. Luqman Chuah Abdullah**  
Faculty of Engineering